These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

134 related items for PubMed ID: 8481509

  • 1. Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
    Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabinowe SN, Eliseo L, Taylor JA, Blättler WA, Epstein CL.
    Blood; 1993 May 01; 81(9):2263-71. PubMed ID: 8481509
    [Abstract] [Full Text] [Related]

  • 2. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM.
    Clin Cancer Res; 1999 Sep 01; 5(9):2392-8. PubMed ID: 10499609
    [Abstract] [Full Text] [Related]

  • 3. Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
    Grossbard ML, Lambert JM, Goldmacher VS, Spector NL, Kinsella J, Eliseo L, Coral F, Taylor JA, Blättler WA, Epstein CL.
    J Clin Oncol; 1993 Apr 01; 11(4):726-37. PubMed ID: 7683045
    [Abstract] [Full Text] [Related]

  • 4. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS, O'Day S, Nadler LM, Grossbard ML.
    Clin Cancer Res; 1998 Nov 01; 4(11):2599-604. PubMed ID: 9829722
    [Abstract] [Full Text] [Related]

  • 5. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
    Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo L, Spector N, Dear K, Lambert JM, Blättler WA.
    Blood; 1992 Feb 01; 79(3):576-85. PubMed ID: 1370636
    [Abstract] [Full Text] [Related]

  • 6. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
    Grossbard ML, Lambert JM, Goldmacher VS, Blättler WA, Nadler LM.
    Cancer Res; 1992 Aug 01; 52(15):4200-7. PubMed ID: 1379121
    [Abstract] [Full Text] [Related]

  • 7. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.
    Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.
    Shah SA, Lambert JM, Goldmacher VS, Esber HJ, Levin JL, Chungi V, Zutshi A, Braman GM, Ariniello PD, Taylor JA.
    Int J Immunopharmacol; 1993 Aug 15; 15(6):723-36. PubMed ID: 7691767
    [Abstract] [Full Text] [Related]

  • 9. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin.
    Roy DC, Perreault C, Bélanger R, Gyger M, Le Houillier C, Blättler WA, Lambert JM, Ritz J.
    J Clin Immunol; 1995 Jan 15; 15(1):51-7. PubMed ID: 7539011
    [Abstract] [Full Text] [Related]

  • 10. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma.
    Preijers FW, De Witte T, Wessels JM, De Gast GC, Van Leeuwen E, Capel PJ, Haanen C.
    Blood; 1989 Aug 15; 74(3):1152-8. PubMed ID: 2473811
    [Abstract] [Full Text] [Related]

  • 11. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer.
    Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V, Ariniello P, Coral F, Ritz J.
    Int J Cancer Suppl; 1994 Aug 15; 8():57-9. PubMed ID: 7515030
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
    Conry RM, Khazaeli MB, Saleh MN, Ghetie V, Vitetta ES, Liu T, LoBuglio AF.
    J Immunother Emphasis Tumor Immunol; 1995 Nov 15; 18(4):231-41. PubMed ID: 8680651
    [Abstract] [Full Text] [Related]

  • 13. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs.
    Liu C, Lambert JM, Teicher BA, Blättler WA, O'Connor R.
    Blood; 1996 May 01; 87(9):3892-8. PubMed ID: 8611717
    [Abstract] [Full Text] [Related]

  • 14. A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254.
    Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD, Cancer Leukemia Group B, Eastern Cooperative Oncology Group.
    Leuk Lymphoma; 2011 Apr 01; 52(4):587-96. PubMed ID: 21275630
    [Abstract] [Full Text] [Related]

  • 15. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
    Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V.
    Blood; 1993 Nov 01; 82(9):2624-33. PubMed ID: 8219217
    [Abstract] [Full Text] [Related]

  • 16. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
    Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ.
    Cancer J; 2000 Nov 01; 6(3):146-50. PubMed ID: 10882329
    [Abstract] [Full Text] [Related]

  • 17. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
    Lynch TJ, Lambert JM, Coral F, Shefner J, Wen P, Blattler WA, Collinson AR, Ariniello PD, Braman G, Cook S, Esseltine D, Elias A, Skarin A, Ritz J.
    J Clin Oncol; 1997 Feb 01; 15(2):723-34. PubMed ID: 9053498
    [Abstract] [Full Text] [Related]

  • 18. Conjugation of blocked ricin to an anti-CD19 monoclonal antibody increases antibody-induced cell calcium mobilization and CD19 internalization.
    Goulet AC, Goldmacher VS, Lambert JM, Baron C, Roy DC, Kouassi E.
    Blood; 1997 Sep 15; 90(6):2364-75. PubMed ID: 9310487
    [Abstract] [Full Text] [Related]

  • 19. Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.
    Grossbard ML, Fidias P, Kinsella J, O'Toole J, Lambert JM, Blattler WA, Esseltine D, Braman G, Nadler LM, Anderson KC.
    Br J Haematol; 1998 Jul 15; 102(2):509-15. PubMed ID: 9695966
    [Abstract] [Full Text] [Related]

  • 20. Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer.
    Lynch TJ.
    Chest; 1993 Apr 15; 103(4 Suppl):436S-439S. PubMed ID: 8384975
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.